Company intelligence / Profile preview

Svelte Medical Systems

New Providence, New Jersey, United Statesradcliffecardiology.com ↗

Ownership: Private
Employees: ~18
Development stage: Other

Overview

Svelte Medical Systems has developed and commercialized extremely low-profile drug-eluting stent systems—SLENDER IDS and DIRECT RX—that have demonstrated excellent clinical outcomes. In the OPTIMIZE IDE study, these devices achieved a 1.5% clinically-driven target lesion revascularization rate at one year—the lowest reported for an investigational DES in the U.S.—with high device success rates and strong safety data.

Therapeutic areas: Cardiovascular
Modalities: DeviceDrug-eluting stent
Industry: Implantable Medical Devices

Partnerships

Asahi Intecc (guidewire technology used in SLENDER IDS)No major pharma/biotech partnerships disclosed.

Beyond the preview

Go deeper on Svelte Medical Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Svelte Medical Systems.

Explore the full profile